ADME Toxicology Testing Market to Reach USD 6.0 Billion by 2030 at 3.9% CAGR | Charles River Laboratories, WuXi AppTec, Eurofins Scientific

The global in vitro ADME toxicology testing market, valued at USD 4.5 billion in 2025, is on track to reach USD 5.2 billion in 2026 and USD 6.0 billion by 2030, growing at a compound annual growth rate of 3.9% over the forecast period. Rising pharmaceutical R&D investment, tightening regulatory requirements for drug approvals, and a growing industry-wide shift toward outsourcing preclinical testing services are all pushing demand higher at a steady, measurable pace.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/adme-toxicology-testing-market/request-sample.html

Market Overview
ADME toxicology testing covers the study of how a drug is absorbed into the body, how it distributes across tissues, how it is metabolized, and how it is excreted. These tests serve as a critical filter during early drug discovery, identifying candidates with viable pharmacokinetic profiles before companies commit to expensive in vivo and clinical programs. Without reliable ADME data, pharmaceutical sponsors risk advancing molecules that will fail later, at far higher cost.

The pressure to reduce late-stage drug attrition is real and quantifiable. Industry studies on terminated drug programs have consistently identified poor pharmacokinetic profiles and ADME-related failures as primary causes of clinical trial dropout. Meanwhile, pharmaceutical R&D spending climbed from approximately USD 128 billion in 2008 to USD 165 billion in 2018, and the trajectory has continued upward since. That growing R&D base, combined with a persistent failure rate in clinical development, is creating durable demand for early-stage testing that can derisk the pipeline.

Over the past decade, the ADME toxicology testing sector has consolidated considerably. Larger contract research organizations (CROs) have systematically acquired smaller, specialized players to broaden their service portfolios and extend their global footprint. Today, more than 90 companies worldwide offer some form of in vitro ADME testing services, with 42% of providers classified as small companies. This mix of scale players and specialists creates a market that competes on breadth of assay capabilities, turnaround time, regulatory expertise, and geographic access.

Key Growth Drivers
Rising pharmaceutical R&D investment and drug development activity. Pharmaceutical and biotechnology companies are running larger, more complex pipelines than at any prior point in the industry's history. The growing incidence of chronic diseases, including oncological, neurological, and cardiovascular conditions, has intensified the push for new therapeutic candidates. ADME toxicology testing sits at the front end of that pipeline, ensuring compounds have the safety and metabolic profiles necessary to justify further development spend.

Stringent regulatory requirements from the FDA, EMA, and international bodies. Regulatory agencies including the US Food and Drug Administration and the European Medicines Agency have made ADME toxicology profiling a mandatory component of drug evaluation submissions. Compliance is not optional. These regulatory mandates act as a structural demand floor for testing services, regardless of broader economic conditions. Companies that want their drug candidates to advance through the approval process must generate this data.

Accelerating outsourcing of preclinical testing to specialized CROs. The high capital cost of ADME testing equipment and the difficulty of maintaining in-house expertise at scale have driven mid-sized and large pharmaceutical companies to rely on specialized contract service providers. Outsourcing partners that offer an integrated suite covering design, synthesis, safety pharmacology, and in vitro ADME testing under a single engagement provide significant operational advantages. This consolidation of services, rather than point-by-point procurement, is becoming the preferred operating model.

Technological advances in high-throughput screening and advanced in vitro systems. High-throughput screening tools and combinatorial chemistry have made ADME profiling faster and more cost-efficient at earlier stages of discovery. Beyond that, significant research investment is flowing into next-generation in vitro systems, including 3D cell culture assays, organ-on-chip platforms, and organoids, all designed to replace or supplement traditional 2D cell culture and animal testing. In April 2025, both Thermo Fisher Scientific and WuXi AppTec launched new high-throughput ADME toxicology platforms featuring advanced automation and data analytics, signaling that the technology investment cycle is accelerating.

Strategic acquisitions and funding rounds expanding service capacity. In January 2025, Evotec SE completed a EUR 150 million funding round to expand its ADME and toxicology testing infrastructure globally. In April 2025, Eurofins Scientific acquired XenoTech, a specialist in ADME and toxicology testing, to deepen its European capabilities in preclinical drug safety evaluations. These moves reflect a broader race among major CROs to secure capacity ahead of anticipated demand growth.

Market Segmentation
The in vitro ADME toxicology testing market segments across four primary service categories: absorption, distribution, metabolism, and excretion. Metabolism and excretion together account for the largest slice of current revenue, with metabolism and elimination alone projected to hold 60.3% of total revenue by 2030. Absorption, meanwhile, is the fastest-growing sub-segment, forecast to expand at a CAGR of 9.3% through 2030 as early-stage permeability and bioavailability screening commands greater attention from drug developers.

By molecule type, small molecules dominate and are projected to account for 56% of revenue by 2030, supported by their ease of administration and the volume of small-molecule programs in active development. The biologics segment is smaller today but growing faster, at a CAGR of 9.0% through 2030, as monoclonal antibodies, bispecifics, and peptide therapeutics move deeper into development pipelines. On the end-user side, pharmaceutical and biotechnology companies hold 67% of market share, while academic and research institutes, though a smaller contributor today, are the faster-growing end-user segment at a CAGR of 9.9% through 2030. By therapeutic area, oncology disorders command the largest share at 42.4% of revenue, with neurological disorders growing fastest at a CAGR of 6.7%.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/adme-toxicology-testing-market/request-quote.html

Regional Insights
North America is the dominant geography in the ADME toxicology testing market, projected to hold 43% of global market share by 2030. The region benefits from the concentration of pharmaceutical and biotechnology headquarters, proximity to the FDA regulatory framework, and the presence of more than 40 established CROs offering ADME services. A senior scientific officer at a US-based CRO noted that while North American clients historically preferred domestic service providers, cross-border outsourcing is becoming more accepted, though the bulk of activity remains centered in this region.

Asia-Pacific is the fastest-growing region, forecast to expand at a CAGR of 8.7% through 2030. Rising interest in outsourcing from North American and European sponsors to lower-cost, high-capability providers in China and India is a primary driver. Companies such as WuXi AppTec, Pharmaron, Shanghai Medicilon, Syngene International, and GVK Biosciences have built substantial in vitro ADME capabilities in the region, enabling clients to access quality preclinical services at competitive pricing. Europe holds meaningful share as well, anchored by CROs with deep regulatory expertise for EMA-compliant submissions.

Competitive Landscape
Key service providers active in the in vitro ADME toxicology testing market include Albany Molecular Research (AMRI), Charles River Laboratories, Eurofins Scientific, Evotec, Galapagos, GVK Biosciences, Pharmaron, Pharmaceutical Product Development (PPD), RTI International, Sai Life Sciences, Shanghai Medicilon, Syngene International, Tecan Group, and WuXi AppTec.

The competitive dynamic in this market is shaped primarily by consolidation and capability breadth. Large CROs are acquiring smaller specialists to broaden their assay menus and geographic reach, while sponsors increasingly prefer integrated partners over point-solution providers. More than 35 partnership deals have been recorded among stakeholders in this field, underscoring how heavily the market is moving toward alliance-based and preferred-provider models. For smaller entrants, differentiation through proprietary technology platforms, particularly in advanced in vitro systems, remains the most viable path to competing against well-resourced incumbents.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/adme-toxicology-testing-market/239.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.